Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1038/s41467-021-25113-5

http://scihub22266oqcxt.onion/10.1038/s41467-021-25113-5
suck pdf from google scholar
34381030!8357797!34381030
unlimited free pdf from europmc34381030    free
PDF from PMC    free
html from PMC    free
PDF vom PMID34381030 :   free

suck abstract from ncbi

pmid34381030
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors #MMPMID34381030
  • Kunze KL; Johnson PW; van Helmond N; Senefeld JW; Petersen MM; Klassen SA; Wiggins CC; Klompas AM; Bruno KA; Mills JR; Theel ES; Buras MR; Golafshar MA; Sexton MA; Diaz Soto JC; Baker SE; Shepherd JRA; Verdun NC; Marks P; Paneth NS; Fairweather D; Wright RS; van Buskirk CM; Winters JL; Stubbs JR; Senese KA; Pletsch MC; Buchholtz ZA; Rea RF; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Lesser ER; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Casadevall A; Carter RE; Joyner MJ
  • Nat Commun 2021[Aug]; 12 (1): 4864 PMID34381030show ga
  • Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma likely reflects the antigenic composition of local viral strains, we hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity. Results of a series of modeling techniques applied to approximately 28,000 patients from the Expanded Access to Convalescent Plasma program (ClinicalTrials.gov number: NCT04338360) support this hypothesis. This work has implications for the interpretation of clinical studies, the ability to develop effective COVID-19 treatments, and, potentially, for the effectiveness of COVID-19 vaccines as additional locally-evolving variants continue to emerge.
  • |Adolescent[MESH]
  • |Adult[MESH]
  • |Aged[MESH]
  • |Antibodies, Viral/immunology[MESH]
  • |Antibody Specificity[MESH]
  • |Antigenic Variation[MESH]
  • |Blood Donors[MESH]
  • |COVID-19/mortality/*therapy[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Immunization, Passive/mortality[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Plasma/*immunology[MESH]
  • |SARS-CoV-2/genetics/immunology[MESH]
  • |Treatment Outcome[MESH]
  • |United States/epidemiology[MESH]
  • |Young Adult[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    4864 1.12 2021